Improving Patient Representation in Clinical Trials Globally

A look at the regulatory landscape for clinical trial diversity

Recruitment of diverse patients from all racial and ethnic backgrounds to join clinical studies is essential in ensuring new medicines are properly evaluated for safety and efficacy across all populations in need of treatment.

Healthcare regulatory bodies across the globe have been responding to this need – releasing mandates to guide life sciences companies as they develop new drugs, therapies, and medical devices to support patient care.

In partnership with FirstWord Pharma, we have conducted an industry poll and analysis to better understand:

• The global regulatory landscape for clinical trial diversity
• The top 3 enrollment challenges
• Life sciences companies’ state of preparedness
• The role of AI and data technology in supporting these efforts

Download the industry report to learn more.